论文部分内容阅读
目的研究希罗达联合多西他赛治疗耐蒽环类药物的晚期乳腺癌的近期疗效和不良反应。方法对52例晚期乳腺癌患者给予希罗达和多西他赛药物联合治疗,希罗达2 500 mg/(m2·d),分2次服用,早晚各1次,饭后30 min口服,连服14 d;多西他赛75 mg/m2,第1天静脉滴注,21 d为1个疗程,4个周期后开始评价疗效和不良反应。结果疾病完全控制者(CR)7例,部分缓解者(PR)27例,稳定者(SD)8例,疾病进展者(PD)10例,总有效率为65.4%,肿瘤控制率为80.7%。不良反应主要为脱发、骨髓抑制、胃肠道反应、手足综合征、皮肤色素沉着、肌肉疼痛,未发生治疗相关性死亡。结论希罗达联合多西他赛对耐蒽环类药物的晚期乳腺癌患者有明显的疗效,不良反应可以耐受,值得临床上推广和应用。
Objective To study the short-term effects and adverse reactions of Xeloda combined with docetaxel in the treatment of advanced breast cancer patients with anthracyclines. Methods Fifty-two patients with advanced breast cancer were treated with Xeloda and docetaxel. The dosage of Xeloda was 2 500 mg / (m2 · d), taken twice daily, once daily and 30 minutes after meal, Even for 14 days; docetaxel 75 mg / m2, the first day of intravenous drip, 21 d for a course of treatment, after 4 cycles began to evaluate the efficacy and adverse reactions. Results Seven patients with complete disease control (CR), 27 with partial response (PR), 8 with stable (SD) and 10 with disease progression (PD) had a total effective rate of 65.4% and a tumor control rate of 80.7% . Adverse reactions were mainly hair loss, myelosuppression, gastrointestinal reactions, hand-foot syndrome, skin pigmentation, muscle pain, and no treatment-related deaths occurred. Conclusion Xeloda combined with docetaxel on anthracycline-resistant patients with advanced breast cancer has a significant effect, adverse reactions can be tolerated, it is worth promoting the clinical application.